IceCure Medical gets IRB approval for ProSense breast cancer study

0 min read | Published on 20 Aug 2026, 05:58 PM |Updated on 20 Aug 2026, 05:58 PM

Reviewed by

Shriram SScanX News Team

Key Highlights

IceCure Medical Ltd. secured Institutional Review Board approval from West Cancer Center & Research Institute for its ChoICE Study. The post-marketing study evaluates ProSense cryoablation for low-risk breast cancer in women aged 70 and above. Patient enrollment is scheduled to begin shortly following the regulatory clearance.

*this image is generated using AI for illustrative purposes only.

IceCure Medical Ltd. (NASDAQ: ICCM) announced on Aug. 20, 2026, that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for its post-marketing study for ProSense cryoablation.

The approval enables patient enrollment for the ChoICE Study, which is expected to commence in the coming weeks. The study focuses on the local treatment of low-risk breast cancer using the company's minimally-invasive cryoablation technology.

ProSense is the first and only medical device to receive U.S. Food and Drug Administration marketing authorization for the local treatment of low-risk breast cancer with endocrine therapy in women aged 70 and above.

Study Details

The ChoICE Study aims to evaluate ProSense cryoablation as an alternative to surgical tumor removal. The technology destroys tumors by freezing them.

Detail	Information
Study Name	ChoICE Study
Location	West Cancer Center & Research Institute, Germantown, TN
Approval Body	JHM-IRB
Device	ProSense cryoablation
Indication	Local treatment of low-risk breast cancer

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the successful enrollment and results of the ChoICE Study influence insurance coverage policies for cryoablation in low-risk breast cancer cases?

What is the projected timeline for IceCure Medical to expand the ChoICE Study to additional clinical sites beyond West Cancer Center?

Could the adoption of ProSense cryoablation as a standard alternative to surgery significantly reduce healthcare costs associated with breast cancer treatment?

Icecure Medical Q2 Results: EPS beats estimate, sales miss

1 min read | Published on 12 Aug 2026, 11:13 PM |Updated on 12 Aug 2026, 11:13 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Icecure Medical reported a Q2 loss of $(1.37) per share, beating the $(1.40) estimate by 2.14%. Revenue grew 69.33% YoY to $889,000 but missed the $1.45 million consensus by 38.7%.

*this image is generated using AI for illustrative purposes only.

Icecure Medical (NASDAQ: ICCM) delivered a mixed second-quarter performance, posting a narrower-than-expected loss per share while revenue growth fell significantly short of market expectations.

The company reported a quarterly loss of $(1.37) per share, which beat the analyst consensus estimate of $(1.40) by 2.14%. This represents a 23.89% improvement over the loss of $(1.80) per share recorded in the same period last year.

Revenue for the quarter stood at $889,000, marking a 69.33% increase from $525,000 in the prior year period. Despite this year-over-year growth, the figure missed the analyst consensus estimate of $1.45 million by 38.70%.

What the Numbers Show

The divergence between earnings and revenue performance highlights a specific dynamic in Icecure’s current financial structure. While the company achieved a notable beat on its per-share loss metric—improving by nearly 24% compared to the previous year—it failed to meet the substantial revenue target set by analysts. The 38.7% miss on sales suggests that while cost controls or operational efficiencies may have contributed to the EPS beat, top-line traction remains below market projections.

Metric	Current Quarter	Prior Year	Change	Analyst Estimate	Beat/Miss
Loss Per Share	$(1.37)	$(1.80)	-23.89%	$(1.40)	Beat
Revenue	$889,000	$525,000	+69.33%	$1.45 million	Miss

The data indicates that while the company is expanding its revenue base significantly year-over-year, it has not yet scaled to the levels anticipated by investors for this reporting period.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific operational efficiencies or cost-cutting measures allowed Icecure to beat EPS estimates despite the significant revenue miss?

How will management adjust its commercialization strategy or sales pipeline to address the 38.7% shortfall against analyst revenue expectations?

Does this divergence between improved margins and lower-than-expected top-line growth signal a need for analysts to revise their long-term growth models for Icecure?